Date post: | 10-Jul-2015 |
Category: |
Health & Medicine |
Upload: | bashir-bnyunus |
View: | 509 times |
Download: | 1 times |
12/17/2014 [email protected] 1
• INTRODUCTION– DEFINITIONS– GOALS– CELL CYCLE– CLASSIFICATION
• PRINCIPLES– PRE-CHEMOTHERAPY ASSESSMENT– COUNSELLING– OPTIMIZATION– MODALITIES– ADMINSTRATION– MANAGEMENT OF SIDE EFFECT AND FOLLOW UP
• COMMONLY USED ANTICANCER REGIMEN• CHEMORESISTANCE• FUTURE TRENDS• CONCLUSION
12/17/2014 [email protected] 2
INTRODUCTION
• DEFINATIONS
– CANCER: A group of disease involving abnormal cell growth with the potential to invade or spread to other part of the body.
– CHEMOTHERAPY: the term chemotherapy is describe as the use of chemicals or drugs to treat cancer.
– CYTOTOXIC DRUG: lysis both normal and cancer cells
12/17/2014 [email protected] 3
INTRODUCTION
• GOALS OF CANCER CHEMOTHERAPY
– Curative: eradication» induction: Given with the intent of inducing complete
remission(eliminate clinical evidence) when initiating a curative regimen
» Consolidation: Repetition of the induction regimen in a patient who has achieved a complete remission.
» Maintainance : Long-term, low-dose, single or combination chemotherapy in a patient who has achieved a complete remission. To prevent recurrence.
– Palliative: » Provide comfort» Improve/prolong quality of life
12/17/2014 [email protected] 4
INTRODUCTION
• CELL CYCLE
Understanding the cell cycle is necessary in cancer chemotherapy
It is a series of events that takes place in a proliferating cell (normal and malignant ) leading to its division and duplication
12/17/2014 [email protected] 5
INTRODUCTION
• Phases of cell cycle
– G₀ Phase(resting phase)
• The cell has not started diving.
• They spend much of their lives in this phase.
• When the cell get a signal to reproduce, they move into the G₁ Phase.
• Limitation to successful eradication of many tumoursby chemotherapy. They re-enter the cycle after therapy.
12/17/2014 [email protected] 7
INTRODUCTION
• G₁ PHASE(Pre-synthetic phase)
– The cell starts to produce proteins and enzymes necessary for DNA synthesis.
– During this phase, RNA synthesis occurs.
– This phase last about 18 to 30 hours.
12/17/2014 [email protected] 8
INTRODUCTION
• S-PHASE(synthetic phase)
– DNA synthesis
– Cellular DNA is duplicated in preparation in preparation for cellular division.
– Length of time S phase is approximately 18-30hrs.
– A weak link, and large number of anticancer agent act.
12/17/2014 [email protected] 9
INTRODUCTION
• G₂ Phase (pre-mitotic phase)
– the cell checks the DNA
– Gets ready to start splitting into 2 cells.
– Here both protein, RNA, and the precursors to the mitotic spindle apparatus are produced.
– This phase is very short 1-2hrs.
12/17/2014 [email protected] 10
INTRODUCTION
• MITOTIC PHASE
– In this phase, which last only 30-60min, the cell actually split into 2 new cells.
12/17/2014 [email protected] 11
INTRODUCTION
• Significance:
– Drugs works mainly on cells that are active(not in the Go)
– Some drugs specifically attack cells in a particular phase
– Determine drug combination
– How often drug is given base on timing.
12/17/2014 [email protected] 12
INTRODUCTION
• CELL CYCLE TIME/GENERATION;
– The amount of time required for cell to move from one mitosis to another.(time to complete one cycle)
– Shorter time results in higher kill when exposed to specific agents.
12/17/2014 [email protected] 14
INTRODUCTION
• Growth fraction
– The percentage of cells actively dividing at a given point in time. High growth fraction results in higher cell kill with exposure to specific agent.
• Tumour burden
– The size of the tumour as determine by the number of cells present. The cancer with a small tumour burden are usually more responsive to therapy. Higher tumour burden the greater the greater the probability of development of resistance.
12/17/2014 [email protected] 15
INTRODUCTION
• REGULATION/ CHECK POINTS• To repair DNA damage ,
• Regulation is lost in cancer cells.
– INHIBITORS:
• Cyclin dependent kinase inhibitors lead generation of P53, Rb which inhibits at G₁/S(restriction point), G₂/Mand M phase.
– PROMOTERS:
• Cyclin dependent kinase + proteins → E2F, cyclin D1, A and B drives the cycle at S and G2 phase
12/17/2014 [email protected] 16
CLASSIFICATION
• Base on– The phases of cell cycle (Bruce and colleagues
1966) • Non-phase dependent
• Phase dependent
– Mechanism of action/biochemical activity• Cytotoxics
• Immunotherapeutic agents
• Targeted therapy
• Steroids and Non-steroidal Hormones
12/17/2014 [email protected] 17
NON-PHASE DEPENDENT
• Toxic to both cycling cells and those in Go phase.
• They kill cells by direct DNA damage
• Kills exponentially with increasing dose.
– Alkylating agents; e.g nitrogen mustard, cyclophosphamide, Procarbazine, Dacarbazine
– Nitrosoureas
– Cisplatin
12/17/2014 [email protected] 18
PHASE-DEPENDENT
• They kill cells only in specific parts of cell cycle. – MITOTIC PHASE
• Vinca alkaloid – vincristin, – vinblastin
• Taxanes– Pacletaxel– Doxetaxel
– S-PHASE• Antimetabolites e.g hydroxyurea, methotraxate, Ara-C, 5-FU, 6-MP, 6-TG• Antibiotics; Actinomycin D, Doxorubicine, epirubicin
– G1- PHASE • Corticorsteroid• Antitumour antibiotics
– G2-PHASE• Antitumour antibiotics
12/17/2014 [email protected] 19
Base on mechanism of action/biochemical activity
CYTOTOXIC AGENTS– Alkylating agent– Antimetabolite– Vinca alkaloids– Antimitotic antibiotic– Taxanes– Miscellaneous compounds
• Antiproliferative enzymes; L-asperaginase• Cisplatine• Nitrosourea
12/17/2014 [email protected] 20
12/17/2014 [email protected] 21
CHEMOTHERAPUETIC AGENT MECHANISM OF ACTION SIDE EFFECT
ALKYLATING AGENTCyclophosphamide,chlorambucil, thiothepa, melphalan etc
Interferes with cross linkage of DNA
MyelosupressionHemorrhagic cystitisSkin rashFlu-like syndrome
ANTIMETABOLITES• Folic acid antagonist e.g
methotraxate• Purine antagonist e.g 6-
mercaptopurine,• Pyrimidine antagonist e.g
5-fluorouracil
Interfere with nucleic acid synthesis because they are analogues of normal metabolites
Mucositis, Nephropathy, Hepato-toxicity & Hand & foot syndrome
VINCA ALKALOID- vincristin, vimblastin
Cause mitotic arrest via spindle fiber inhibition
Neuropathy, constipation, Mucositis & myelosuppresion
ANTITUMOUR ANTIBIOTIC e.g adramycin, daunorubicin,actinomycin D, bleomycin
Bind to DNA to block RNA production
cardio toxicity, pulmonary toxicity & myelosuppresion
12/17/2014 [email protected] 22
CHEMOTHERAPEUTIC AGENT MECHANISM OF ACTION SIDE EFFECT
TAXANES e.g paclitaxel, docetaxel
Bind to tubulin. Stop disassembly of mitotic spindle
neuropathy skin rash & myelosuppresion
MISCELLANEOUS L-AsparaginaseNitrosoureaCis-platinium
12/17/2014 [email protected] 24
IMMUNO-THERAPUETIC AGENTS
MECHANISM OF ACTION CLINICAL USE
Levamisole(antihelmenthic)
immunomodulator Adjuvant in colonic cancer in combination with 5-FU
Interleukin-2(IL-2) Enhances NK-cells and tumour specific T-cells
MelanomaRenal cell caNeuroblastomaNHL
Interferon Enhance NK-cells Re-expression of HLA gene
Kaposi’s sarcomaMultiple myelomaLeukemia
BCG Stimulate immune response
CIS of the bladder,
12/17/2014 [email protected] 25
TARGET THERAPY MECHANISM OF ACTION CILNICAL USES
SMALL MOLECULES GefitinibErlotinib
Inhibits EGFR tyrosine kinase thereby inhibiting growth of cancer cells
Non-small cell cancer of the lungs
MONOCLONAL ANTIBODIESTrastuzumab(Herceptin)Rituximab(mabthera)Bevacizumabcetuximab
Selectively kill tumour cellsexpressing certain receptors
Trastuzumab is use Her-2positive breast cancer
12/17/2014 [email protected] 26
HORMONE CLINCAL USES
ANTI-ANDROGENSFlutamideoestrogen
Use with gosereline in the treatment of metastatic prostate cancer
ANTI-ESTROGENTamoxifenPure anti-oestrogen (fasodex)
Breast cancer
SELECTIVE AROMATASE INHIBITORSAnastrozole
2nd line in ER/PR +ve breast ca
AMINOGLUTETHIMIDE Breast and adrenal ca
PROGETINSMedroxyprogesterone acetate
Breast and endometrial
LHRH analogueGoserelin
Prostate and breast ca
CORTICOSTEROIDSDexamethasoneprenisolone
Breast ca as acombination, treatment of hypercalcemia, raise ICP from brain metastesis
PRINCIPLES
– PRE-CHEMOTHERAPY ASSESSMENT
– COUNSELLING
– OPTIMIZATION
– MODALITIES
– ADMINSTRATION
– MANAGEMENT OF SIDE EFFECT AND FOLLOW UP
12/17/2014 [email protected] 27
PRE-CHEMOTHERAPY ASSESSMENT
• AIM
– Establish diagnosis
– Fitness of patient
• METHODS
– Clinical evaluation
– Laboratory test
12/17/2014 [email protected] 28
PRE-CHEMOTHERAPY ASSESSMENT
• CLINICAL EVALUATION
– History
• Detail history
• Systemic involvement
• Co-morbidities
• Performance status
12/17/2014 [email protected] 29
Performance status
• An attempt to quantify the general well being and daily activity of a cancer patient.– whether they can receive chemotherapy
– whether dose adjustment is necessary, and
– as a measure for the required intensity of palliative care.
– measure of quality of life
– Utilises two main scales ; Karnofsky score and Eastern Cooperative Oncology Group (ECOG) system
12/17/2014 [email protected] 30
Performance scaleECOG KARNOFSKY
0: fully active, able to carry on all predisease performance without restriction.
100% - Normal; no complaints; no evidence of disease.
90% - Able to carry on normal activity; minor signs or symptoms of disease
1 – Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature. For example, light housework, office work)
80 %- Normal activity with effort; some signs or symptoms of disease.
70% - Cares for self; unable to carry on normal activity or to do active work
2 – Symptomatic, <50% in bed during the day Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours)
60% - Requires occasional assistance, but is able to care for most of his personal needs.
50 %- Requires considerable assistance and frequent medical care.
3 – Symptomatic, >50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours)
40% - Disabled; requires special care and assistance.30% - Severely disabled; hospital admission is indicated although death not imminent.
4 – Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair)
20% - Very sick; hospital admission necessary; active supportive treatment necessary.10% - Moribund; fatal processes progressing rapidly.
5 – Death 0 - Dead31
PRE-CHEMOTHERAPY ASSESSMENT
• Physical examination
– The extent of primary and metastatic disease via the general and thorough systemic examination
– Body surface area
•√ 𝑤𝑒𝑖𝑔ℎ𝑡(𝑘𝑔) ×ℎ𝑒𝑖𝑔ℎ𝑡 (𝑐𝑚)
3600
12/17/2014 [email protected] 32
PRE-CHEMOASSESSMENT
• Laboratory test– Diagnostic: histology– Extent:
» imaging ;CXRay, CT, MRI,PET,SPET» Uss» LFT
– Baseline:» FBC
• PCV- 30%• WBC<2.5, 2.5-3.9 >4.0 ×10⁹/L• PLT <75, 75-150, >150 ×10⁹/L
» U&Ecr» Stool microscopy- Strogiloides Stercoralis
– Others; depend on the type of cancer e.g tumour markers
12/17/2014 [email protected] 33
COUSELLING
• Adequate counseling– Disease explained in simple terms that can be
understood– Extent – Plan of treatment – Side effect expected – Fair idea of prognosis
• Opportunity given to ask adequate questions and get accurate answers
• A professional counsellor/ psychologist should be involved
12/17/2014 [email protected] 34
COUNSELLING
• The aim of the therapy most clearly be stated to patient and relative
– Curative
– Palliative
• Modalities of treatment
• INFORMED CONSENT obtained
12/17/2014 [email protected] 35
MODALITIES
• Modality is selected base on the type and stage of the cancer.
• Neoadjuvant
• Adjuvant
• Multimodality
– Surgery
– Chemo-radiation
12/17/2014 [email protected] 36
OPTIMIZATION
– Anaemia
– Dehydration
– De-worming
– Malnutrition
– Control of infection
– Dialysis -Uremia
12/17/2014 [email protected] 37
ADMINISTRATION
• Choice of agents
– Type of cancer
– The stage
– Age
– Clinical state of patient
– Co-morbidities
– Treatment in the past
– Drug interactions
12/17/2014 [email protected] 38
ADMINSTRATION
• The ORDER is written and signed– Name, diagnosis, drug combination, number of cycles and
duration
• DOSE– Calculate base on body surface area– Dose prescription
• Standard dose ; anticipate mild side effect, minimal supportive care • High dose; above standard, anticipated side effect, requires
supportive care; G-CSF, blood transfution• Ablative dose; ablation of tumour and stem cells, in conjunction with
stem cell transplantation • Adjusted dose; reduced dose in renal impairment.
12/17/2014 [email protected] 39
ADMINISTRATION
• ROUTES OF ADMINSTRATION– Oral – Intravenous
• Bolus • Infusion
– Arterial infusion– Extracorporeal limb perfusion– Intracavitory– Intrathecal– Subcutaneous – intramuscular– Topical
12/17/2014 [email protected] 40
ADMINISTRATION
• Pre-chemotherapy medications
– IV fluids (allopurinol, alkylanizaton of urine) –prevent risk of tumour lysis syndrome.
– Antiemetic: Ondansetron 0.15mg/kg given 30min before commencement.
– Antidotes; leucovorin antidote for antifolate-metothraxate. (Co-administered, after admistration)
12/17/2014 [email protected] 41
ADMINISTRATION
• MODES/METHODS
– Single agent continuous therapy
• Little value in modern cancer management
• - Low response rates.
• - Complete remissions were infrequent.
• - Kill small fractions of tumour cell
• - Potentiates the development of drug resistance
12/17/2014 [email protected] 42
TREATMENTNU
MB
ER
OF
CE
LLS
KEY:
Normal cells
Tumour cells
Time
Effect of a Single Course of Cytotoxic Therapy on Tumour & Normal Tissues.
CYCLICAL CHEMOTHERAPY
• Drugs is given in cyclical fashion
• To prevent drug resistance
• This gives normal cells time to recover from the drug’s side effects.
12/17/2014 [email protected] 44
TREATMENTNU
MB
ER
OF
CE
LLS
KEY:
Normal cells
Tumour cells
Rx RxRx
321
Time
Effect of Multiple Courses of Cytotoxic Therapy on Normal Tumour Cell population
COMBINATION CHEMOTHERAPY
Superior to single drug chemotherapy
Considerations:
• Drug should be active as a single agent
• Avoid drugs with similar toxicity
• To reduce toxicity
• Use drugs with different mech. of actions
• Use maximum therapeutic doses
12/17/2014 [email protected] 46
ADMINISTRATION
• MONITORING– Premedication vital signs take, then regular monitaring
– Mainly cardiovascular- cardiotoxicity• Tarchcardia
• Arrhythmias
• S3 gallop
• Chest pain, tightness – acute coronary sydrome
• Esp anthracyclins, trastuzumab, cyclophophamide, pacletaxel
– Nausea, vomiting
– Breathing pattern
– Antidotes and emergency drugs
12/17/2014 [email protected] 47
ADMINISTRATION
• SAFETY– Chemotherapeutic agent are harzardous
• Mutagenic
• Teratogenic
• Carcinogenic
• Skin irritation
– Gloved, goggle and gowns when administering. In a good ventilation to prevent inhalation of droplets when preparing.
– Care in handling patient urine and faeces
12/17/2014 [email protected] 48
Management of side effects
• Side effects results from; lyses of normal cells, depends on the type of drug, dose, route and individual response.
• Rapidly dividing cells are more affected; blood cells, hair follicle, digestive tract and reproductive tracts.
12/17/2014 [email protected] 49
Management of side-effects
• LOCAL– Flare reaction/thrombophebitis
• Irritation along the tracts. Triggering inflammation along the tract and surrounding skin.
– Vesiculation• From extravasation into surrounding subcutaneous tissue leading to vesicles
which subsequently ulcerates.• Chemical burns
– Treatment ; (easily prevented- good vein, ensure no leakage b4 chemo, set fresh not pre-existing line, monitor line, start with vesicant.)• Stop immediately• Antihistamine• Hydrocortisone • Analgesics• Care of ulcer when developed
12/17/2014 [email protected] 50
Management of side effect
• SYSTEMIC– Haemopoietic; Myelosuppresion
• Treat emergencies- aneamia, throbocytopenia, treat infection
• Treatment with CSF
– Gastrointestinal; nausea, vomiting, anorexia, constipation, diarrhea• 5-HT antagonist- ondasetron
– Hypergycalcaemia;• Bisphosphonate
• Corticostiroid
12/17/2014 [email protected] 51
• Urinary- hemorrhagic cystitis- mesna
• Neurologic –peripheral neuropathy
• Cardiovascular ; Cardiomyopathy
• Respiratory ; pulmonary fibrosis
• Reproductive; infertility, menorrhagia.
12/17/2014 [email protected] 52
FOLLOW-UP
• Complication
– History
– Physical examination
– Laboratory investigation- repeat baseline and histology, tumour marker
– Treat complication as they arise
• Response
• Resistance
12/17/2014 [email protected] 53
RESPONSE
WHO Objective response – Change in longest diameter of the target lesion
Complete; Disappearance of all known disease, confirmed at ≥ 4 weeks.
Partial; ≥ 50% decrease from baseline, confirmed at ≥ 4weeks
Progressive ; ≥ 25% increase in one or more lesions or appearance of new lesions
Stable; no change
12/17/2014 [email protected] 54
CHEMORESISTANCE
• Reduction in the effectiveness or failure of response could be primary or secondary
• Depend on grade of tumour, type of drug and dose use.
• Mechanisms – Overexpression of Adenosine triphosphate binding
cassette
– Inactivation of apoptosis
– Inactivation of nuclear factor- kB transcription factor
– Cancer stem cell
12/17/2014 [email protected] 55
COMMONLY USED ANTICANCER REGIMEN
• Breast cancer– CMF– CAF/VAC-P– TAXANE BASED eg
» paclitaxel and xeloda» Paclitaxel, cyclophosphamide and doxorubicine
• Gastric – ECF
• Wilm’s– Methotrexate or dactinomycin, douxorubicin and
vincristin
12/17/2014 [email protected] 56
FUTURE TRENDS
• Tumour vaccine- stimulate the body to produce CD4 cells which suppresses tumour cells e.g sipuleucel-T, prostate G-vax still under investigations
• Gene therapy
12/17/2014 [email protected] 57
CONCLUSION
• Cancer chemotherapy is an important component in cancer management singly or in multi-modal therapy. They are toxic to normal tissues hence require knowledge of drugs, early recognition, and management of side effect
• Adequate counseling is required for compliance to treatment.
12/17/2014 [email protected] 58
REFERENCES
• E.A Badoe et al, “Principles and Practice of surgery including pathology in the tropics” 4th edition, Assembly of God Literature Center ltd, 2009
• M.A.R Al-Fallouji; “Postgraduate Surgery the candidate guide”. 2nd Edition. Rced Educational and Professional Pub. Ltd 1998
• Sriram Bhat S “SRB manual of surgery” 4th edition Jaypee Brothers Medical Publishers (P) Ltd
• Guidelines for the Safe Prescribing, Dispensing and Administration of Cancer Chemotherapy “Clinical Oncological society of Australia” Nov. 2008
• Joseph O. Jacobson et al,” American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards” journal of clinical oncology. volume 27 number 32 november 10 2009.
• www.slideshare .net
• www.wikepedia .org
12/17/2014 [email protected] 59